Stocks/Toronto Stock Exchange/MRK

MRK

Toronto Stock Exchange

Merck CDR (CAD Hedged)

Common Stock

$24.50

CAD

+0.00 (%)

Last updated: 1/8/2026

Price Chart (30 Days)

$1.19 (4.94%)
9 day period
$23.75$24.52$25.30Dec 24Jan 2Jan 8

Key Statistics

Market Cap

$264.21B

52W High

$25.30

52W Low

$16.37

P/E Ratio

11.75

50 Day MA

$0.00

200 Day MA

$0.00

Beta

-

Dividend Yield

-

Technical Indicators

Price vs 50-Day SMA

Above 50 SMA

Price vs 200-Day SMA

Above 200 SMA

Recent Price History

DateOpenHighLowCloseVolume
1/8/2026$25.00$25.30$24.77$25.303,684
1/7/2026$24.85$25.10$24.40$24.501,832
1/6/2026$24.51$24.75$24.51$24.619,905
1/5/2026$24.38$24.38$24.12$24.235,172
1/2/2026$23.77$24.03$23.67$24.028,042
12/31/2025$24.00$24.00$23.75$23.75528
12/30/2025$24.07$24.07$24.07$24.07150
12/29/2025$24.02$24.16$24.02$24.114,682
12/24/2025$23.76$24.11$23.76$24.11519

About Merck CDR (CAD Hedged)

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Financials

Revenue (TTM)
$0
EBITDA
-
Profit Margin
0.00%
ROE (TTM)
3950.93%
EPS (Diluted)
0.00
Book Value
-

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report